Forte Biosciences (FBRX) Common Equity (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Common Equity of $42.1 million for Q1 2026, up 9.56% year-over-year from $38.4 million in Q1 2025, and down 30.97% quarter-over-quarter from $61.0 million in Q4 2025.
Forte Biosciences (FBRX) Common Equity (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Common Equity for 11 consecutive years, with $42.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 9.56% year-over-year to $42.1 million; the TTM figure through Mar 2026 stood at $42.1 million (up 9.56% YoY), while the FY2025 annual figure was $61.0 million, up 16.22% from the prior year.
- Common Equity declined to $42.1 million in Q1 2026 per FBRX's latest filing, from $61.0 million in the prior quarter.
- Across five years, Common Equity topped out at $98.6 million in Q2 2025 and bottomed at $9.4 million in Q3 2024.
- Historically, Common Equity has averaged $42.7 million across 5 years, with a median of $38.8 million in 2022.
- Annual changes were most pronounced in 2024 — Common Equity tumbled 76.82% — and 2025, when it soared 797.9%.
- Forte Biosciences' Common Equity stood at $38.8 million in 2022, then decreased by 9.03% to $35.3 million in 2023, then soared by 48.61% to $52.5 million in 2024, then grew by 16.22% to $61.0 million in 2025, then tumbled by 30.97% to $42.1 million in 2026.
- Business Quant data shows FBRX's Common Equity at $42.1 million in Q1 2026, $61.0 million in Q4 2025, and $84.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 183.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 183.79 Mn |
| Mar 31, 2026 | 42.10 Mn |
| Dec 31, 2025 | 60.99 Mn |
| Sep 30, 2025 | 84.10 Mn |
| Jun 30, 2025 | 98.61 Mn |
| Mar 31, 2025 | 38.43 Mn |
| Dec 31, 2024 | 52.48 Mn |
| Sep 30, 2024 | 9.37 Mn |
| Jun 30, 2024 | 16.96 Mn |
| Mar 31, 2024 | 28.69 Mn |
| Dec 31, 2023 | 35.31 Mn |
| Sep 30, 2023 | 40.41 Mn |
| Jun 30, 2023 | 24.88 Mn |
| Mar 31, 2023 | 32.95 Mn |
| Dec 31, 2022 | 38.82 Mn |
| Sep 30, 2022 | 42.84 Mn |
| Jun 30, 2022 | 38.21 Mn |
| Mar 31, 2022 | 40.05 Mn |
| Dec 31, 2021 | 41.55 Mn |
| Sep 30, 2021 | 43.65 Mn |